One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Journals package 1months
-
http://medilib.ir
- Duration of Time : 31 Day
Price : 100$- Special Price : 50$
Efruxifermin: one step closer to disease-modifying therapy in fibrotic MASH
A crisis of credibility: the global cost of US vaccine misinformation
A new definition of human health is needed to better implement One Health
Unifying forces to strengthen pandemic preparedness: a call for a Global Pandemic Risk Observatory
War wounds caused by explosive weapons in Gaza: data from a 2024 study by Médecins Sans Frontières
Paediatric meningitis outbreak in Gaza amid health system collapse
Clinical, ethical, and quality-of-life outcomes in unresectable hepatocellular carcinoma: the LEAP-012 trial
Clinical, ethical, and quality-of-life outcomes in unresectable hepatocellular carcinoma: the LEAP-012 trial
Clinical, ethical, and quality-of-life outcomes in unresectable hepatocellular carcinoma: the LEAP-012 trial – Authors' reply
Spironolactone versus placebo in patients undergoing maintenance dialysis (ACHIEVE): an international, parallel-group, randomised controlled trial
Spironolactone in patients on chronic haemodialysis at high risk of adverse cardiovascular outcomes (ALCHEMIST): a multicentre, double-blind, randomised, placebo-controlled trial and updated meta-analysis
Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial
The Lancet Commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment
